no worries. I've done further reading and it appears to me Edwards is driving two product lines, the Sapien models and the Resilia models. Sapien X4 clinical development this year, Resilia Inspiris/Konect already approved and being promoted as a premium models? Edwards spends $US200m a quarter on R&D! Medtronic looking to release Evolut FX later this year. A lot of working going into making better models which reduce or eliminate paravulvar leakage which appears to be a common problem with these types of valves.
I found this PDF which lists next generation TAVR devices. The Boston Scientific valve is obviously no longer available.
https://www.nytranscathetervalves.org/wp-content/uploads/2020/12/Abizaid-Current-Update-on-Next-Generation.pdf
Ann: Anti-Calcification Study, page-71
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |